GSK acquires RAPT Therapeutics for $2.2bn

In a bid to bolster its immunology portfolio, GSK is acquiring food allergy specialist RAPT Therapeutics for up to $2.2bn. This buyout, which is one of the first major deals of 2026, will see the UK-based pharma pay $58.00 per share at closing, reaching an approximate aggregate equity value of $2.2bn. This will see GSK pay significantly more for each of RAPT’s stocks compared with its closing stock value on 16 January, which sat at $35.10 per share. The drug in the spotlight of this deal is long-acting, ...